Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
Paris Margaritis, Chief Scientific Officer at GeneVentiv Therapeutics, Inc, shared a post on LinkedIn:
“It was a pleasure and an honor to participate in the World Federation of Hemophilia Workshop on New Technology and Gene Therapy in Montréal, Canada.
I was delighted to present GeneVentiv Therapeutics recent preclinical work on GENV-HEM, an AAV-based gene therapy approach expressing FVa for hemophilia A, with or without FVIII inhibitors.
It was a wonderful opportunity to exchange ideas and engage in stimulating scientific discussions, particularly during the panel discussion. It was also great to reconnect with colleagues and friends who share a commitment to advancing therapies for people living with bleeding disorders.
Many thanks to the World Federation of Hemophilia and the Program Committee for the invitation and for putting together such an engaging and productive meeting.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series
-
Nov 20, 2026, 17:16Raising Awareness of Bleeding Disorders in Women Through the Red Flag Campaign – Perth Blood Institute
-
Nov 20, 2026, 15:11Muhammet Özbilen: Rivaroxaban vs Apixaban – The Menstrual Bleeding Difference
-
Nov 20, 2026, 14:54Fostamatinib in Immune Thrombocytopenia: Targeting Spleen Tyrosine Kinase to Reduce Platelet Destruction
-
Nov 20, 2026, 14:37Giuseppe Leone: The Evolving Treatment Landscape of Adult ITP
-
Nov 20, 2026, 14:25Sameer A.: When Heparin Triggers Thrombosis – A Case of HIT